Results 101 to 110 of about 2,055 (188)

Tislelizumab plus AG regimen for long-term CR in 2 patients with metastatic BRCA-mutation pancreatic cancer: A case report. [PDF]

Medicine (Baltimore)
Gao F, Xu X, Chen C, Lv L.
europepmc   +1 more source

Response to PARP Inhibition in <i>BARD1</i>-Mutated Refractory Neuroblastoma. [PDF]

N Engl J Med
Cupit-Link M, Hagiwara K, Nagy M, Koo SC, Orr BA, Ruppin E, Easton J, Zhang J, Federico SM.   +8 more
europepmc   +1 more source

Matching-adjusted indirect comparisons of PARP inhibitor combinations in metastatic castration-resistant prostate cancer across key populations. [PDF]

Oncologist
Castro E, Wang D, Paganelli S, Haltner A, Su N, Kirker M, Chang J, Samjoo IA.   +7 more
europepmc   +1 more source

Clinical and molecular determinants of response to maintenance olaparib for primary and recurrent epithelial ovarian carcinoma. [PDF]

Clin Transl Oncol
Wagar MK, Bharucha K, Montemorano L, Huffman LB, Godecker AL, Barroilhet LM.   +5 more
europepmc   +1 more source

Design and Synthesis of new Inhibitors of Carcinogenic Processes [PDF]

, 2011
ABBATE, Ilenia
core  

A prospective study of serum folate levels in patients with solid tumors treated with olaparib. [PDF]

Oncologist
Shammo J, Owczarzak L, Yun NK, Winkelman L, Basu S, Rao R, Ahmed A, Dewdney S, Cobleigh M, Usha L.   +9 more
europepmc   +1 more source

4-(4-Methylphenyl)-2-(prop-2-yn-1-yl)phthalazin-1(2 H [PDF]

Abd alla, Awadallah, B. Kalluraya, Bausch, D. Revannasiddaiah, Khalil, Kim, M. K. Usha, Macrae, N. K. Lokanath, P. C. Shyma, Ryu, S. Madan Kumar, Sheldrick, Spek   +14 more
core   +1 more source

Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer. [PDF]

Future Oncol
Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, Szczylik C, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Lin X, Healy CG, Di Santo N, Zohren F, Fizazi K.   +20 more
europepmc   +1 more source

Pembrolizumab plus chemotherapy followed by maintenance with or without olaparib as first-line treatment for advanced BRCAwt ovarian cancer with LOH-low: a international cost-effectiveness analysis. [PDF]

J Ovarian Res
Liu K, Zhou X, Zhu Y, Zhu H.
europepmc   +1 more source

Phase I Dose-Escalation Trial Combining Olaparib and Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer. [PDF]

Clin Cancer Res
Rimner A, Lok BH, Gelblum DY, Kotecha RR, Shin JY, LaPlant Q, Shepherd AF, Shaverdian N, Simone CB, Ng VJ, Ionescu A, Yu HA, Daly R, Offin MD, Yorke ED, Ginsberg MS, Zhang Z, Wu AJ, Rudin CM.   +18 more
europepmc   +1 more source